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Immunolocalization of platelet-derived growth factor receptor-β (PDGFRβ) and pericytes in
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL)
Aims: Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)
is identified by aggregates of NOTCH3 extracellular
domain (N3ECD) along capillaries and the deposition of
granular osmiophilic material (GOM). We assessed the
pattern of distribution of pericytes in relation to N3ECD
deposits in cerebral microvessels of CADASIL subjects.
Methods: We assessed post mortem brains from (n = 50)
subjects with CADASIL, cerebral small vessel disease,
and similar-age cognitively normal and older controls.
Immunohistochemical and immunofluorescent staining
methods were used to study the distribution and quantify
immunoreactivities of the platelet-derived growth factor
receptor-β (PDGFR-β) (for pericytes) and microvascular
markers in the frontal cortex and white matter. Results:
PDGFR-β antibody stained cells typical of pericytes in cap-
illaries and small arterioles in both the grey and white
matter. PDGFR-β reactive pericytes adopted ‘crescent’
morphology wrapped closely around capillary walls
readily evident in cross-sections. We noted considerable
overlap between PDGFR-β and N3ECD imunoreactivi-
ties in capillaries. Quantitative analysis of PDGFR-β
immunoreactivity revealed significant differences in
PDGFR-β %A in CADASIL compared with young controls
(P < 0.05). PDGFR-β %Awas further positively correlated
with the basement membrane marker collagen IV
(r = 0.529, P = 0.009), but was not associated with
GLUT-1, the marker for endothelial cells. Conclusions:
Our results suggest increased expression of PDGFR-β
immunoreactive pericytes in cerebral microvessels in
CADASIL compared with similar age controls. While we
cannot confirm whether PDGFR-β-expressing pericytes
produce N3ECD and hence GOM, our findings demon-
strate that up-regulation of pericyte-like cells is associated
with microvascular changes, including loss of vascular
smooth muscle cells in CADASIL.
Keywords: CADASIL, capillaries, dementia, pericyte, platelet-derived growth factor receptor, vascular smoothmuscle cell,
vascular dementia
Introduction
Cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leukoencephalopathy (CADASIL) is
themost commonhereditary strokedisorder, affectingover
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600 families worldwide [1–3]. It is caused by mutations
in theNOTCH3geneandresults inaggregationof NOTCH3
extracellular domain in granular osmiophilic material
(GOM) within blood vessel walls, degeneration of vascular
smooth muscle cells (VSMCs) and a small vessel disease
(SVD) type dementia [1,2,4]. We have previously shown
that capillary beds are also associated with an accumu-
lation of N3ECD deposits, which mostly represent GOM
in CADASIL. It has been previously postulated that
pericyte-like cells, owing to the similar developmental
lineage as VSMCs, may produce GOM. Previous electron
microscopy (EM) studies have also shown that amor-
phous GOM is located at the cell membranes of pericyte-
like cells [5–7].
Pericytes are located abluminal to endothelial cells
within the basement membrane of capillaries, pre-
capillary arterioles and post-capillary venules [8–10].
They have multiple functions beyond contractile control
of blood flow, providing paracrine signals during
angiogenesis and some phagocytic activity. Pericytes are
further specialized as a vital component of the blood–
brain barrier (BBB) and central nervous system (CNS)
capillaries have around 22–32% pericyte coverage,
second in density only to capillaries of the retina [11,12].
Pericyte processes wrap around the length of capillaries
and form close contacts with endothelial cells through
peg and socket junctions, gap junctions, and adhesion
plaques. They are thought to contract the capillary in
response to neuronal activity and during ischaemia [13].
Three major signalling pathways have been identified
between endothelial and pericyte cell populations during
angiogenesis: transforming growth factor-β, angiopoietin
and platelet-derived growth factor (PDGF) [14]. In par-
ticular, PDGF subunit B expressed by endothelial cells
recruits pericytes expressing PDGF receptor-β (PDGFR-β)
to the capillary wall during vessel maturation in
angiogenesis. Blockage of this signal results in fewer
recruited pericytes to the vessel, causing vessel leakage,
tortuosity, formation of microaneurysms and micro-
bleeds [15]. NOTCH3 is also expressed in pericytes and
perturbed NOTCH3 signalling during development
results in reduced pericyte recruitment to capillaries
[16]. In accord with angiogenic factors, PDGFR-β expres-
sion is activated following ischaemic injury, where
PDGFR-β signalling surprisingly promotes transforma-
tion of VSMC to a different phenotype and loss of con-
tractile function [17,18]. Notch1 expression has
similarly been shown to be activated by ischaemia with a
similar effect to promote differentiation of VSMCs to dif-
ferent phenotypes [19]. In contrast, the expression of
NOTCH3 is reduced following vascular injury [20]. A
study exploring cultured VSMCs derived from a CADASIL
patient reported that there was a negative feedback
mechanism between the expression of NOTCH3 and
PDGFR-β [21], suggesting that NOTCH3 and PDGFR-β
signalling may act antagonistically to control VSMC dif-
ferentiation state. Another recent study has further iden-
tified signature genes downstream of Notch activity in
retinal pericytes and suggests that tight regulation of
Notch signalling is crucial for pericyte survival [22]. In
an effort to explore some of these mechanisms [2], we
primarily aimed to localize and quantify the expression of
PDGFR-β in CADASIL in relation to N3ECD and compare
against similar age relevant controls.
Methods
Subjects and tissues
Table 1 provides demographic details and diagnoses in the
subjects. The mean ages of the CADASIL and young
control subjects were not different. Available case notes
and radiological reports indicated that CADASIL subjects
showed extensive white matter (WM) changes consistent
with small vessel disease (SVD) of the brain and met the
minimum criteria for cognitive impairment used in our
post-stroke survivors study [24]. CADASIL diagnosis was
confirmed by the presence of NOTCH3 gene mutations or
the presence of granular osmiophilic material (GOM) in
arteries within skin biopsies [25]. None of the controls
had neurological or pathological evidence for cerebrovas-
cular disease or neurodegenerative disorder. Tissue blocks
from the frontal lobe of the CADASIL subjects and age-
matched controls were collected from four sources. In
addition to the Newcastle Brain Tissue Resource (NBTR),
Newcastle University, Campus for Ageing and Vitality, we
obtained cases from the MRC London Brain Bank for
Neurodegenerative Diseases, theMRC SuddenDeath Brain
and Tissue Bank, University of Edinburgh and Neurology
Department, Ludwig Maximilians University, Germany.
Tissue from SVD subjects and older controls were obtained
from the NBTR. Use of brain tissue was approved by the
local research ethics committee of the Newcastle upon
Tyne Hospitals NHS FoundationTrust, the NBTR commit-
tee, and the ethics committees overseeing the Brain Banks
at the other respective sites.
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Immunohistochemistry
Formalin-fixed paraffin-embedded postmortem brain tissue
from the frontal lobe, Brodmann Area 9, was serially cut
into 10-μm thickness sections and immunostained
with various antibodies, including PDGFR-β antibody
(PDGFR-β at 1:200 dilution, clone 42G12, Product
#AF385, R&D Systems, Minneapolis, MN, USA), NOTCH3
extracellular domain [N3ECD, A1-1 antibody (1:1000
dilution, a gift from A. Watanabe)], smooth muscle alpha
actin (SMA), glucose transporter-1 (GLUT-1) and collagen
IV (COL4) as described previously [26]. Specificity of the
PDGFR-β antibody was verified per manufacturer’s
datasheet. Upon immunoblotting of frontal cortical
samples from a young and old control, 95-year-old male,
andaCADASIL subject,wenoted themolecularweight size
bands of 150 kDa. α/β tubulin bands detected at 55 kDa
were recognized as loading controls (data not shown). Spe-
cificities of antibodies to vascular markers were ascer-
tained as described previously [26,27].
Image acquisition and analysis
Images of capillary beds or regions of interest (ROIs) within
the tissue sections were captured on a Zeiss Axioplan 2.0
microscope and Image capture software (Infinity Capture
V4.6.0, Lumenera Corporation, Ottawa, Ontario, Canada),
taking care to avoid larger arterioles >50 μm external diam-
eter. Immunohistochemical staining was quantified using
Image Pro Plus (V.4.0; Media Cybernetics, Silver Spring, MD,
USA).Weassessed thepercentarea (%A) for eachcase fromat
least 10 ROI images representing the vascular area stained
with PDGFR-β (as PDGFR-β %A). To test the quality of the
immunoreactvities between individual sections and cases,
andweascertained the integratedoptical density (IOD).There
were no significant differences in IOD values between
CADASIL and control samples, however. We also found that
therewere no relationships between the immunohistochemi-
cal staining of PDGFR-β and length of fixation, or post
mortem interval, between the groups. All of the histo-
pathological analyses were performed blind to the operator.
Immunofluorescence (IF)
Six-μm thick formalin-fixed paraffin-embedded tissue sec-
tions were cut serial to the sections used for immunohisto-
chemistry, and underwent antigen retrieval in either 3 mM
EDTA ethylenediaminetetra acetic acid buffer (pH 8.0) and
blockedwith 10%normal horse serum/PBS ‘phosphate buff-
ered saline’. Sections were incubated overnight at 4°C with
primary antibodies to anti-PDGFR-β (1:200 dilution), anti-
smooth muscle alpha-actin (SMA, 1:500, Clone 1A4, Dako,
Cambridge, UK), anti-Notch-3 extracellular domain (N3ECD,
A1-1 at 1:10 000), glucose transporter-1 (GLUT-1, 1:200,
PA1-21041 Thermo Scientific, Rockford, IL, USA). Sections
werewashed inPBSand incubated for45 minwithoneof the
following secondary antibodies: goat anti-mouse IgG conju-
gated DyLight 488, (1:200, product no. 35502; Thermo Sci-
entific); goat anti-rabbit IgG conjugated DyLight 550 (1:200,
Table 1. Demographic details of the cases and controls
Young controls CADASIL Old controls SVD
N (Total = 50) 12 11 12 10
Mean age (years) (range) 57.5 59.6 84.0 82.4
(46–65) (44–69) (78–94) (67–96)
Gender (M/F) 6/5 7/4 3/9 4/6
Age at onset (years) 46 N/A
Duration of disease 10.8 years 7–9 years
Main causes of death/notable
clinical features
Heart attack, cancer,
renal failure,
infection
Broncho-pneumonia,
stroke/CADASIL
Heart failure, cancer,
ischaemic bowel
infection
Vascular dementia,
heart failure, cancer,
GI bleed, sudden death
Neurofibrillary Braak Stage 0 0 0–4 1–4
Mode WM Score* (range) 1 3 2 3
(1–2) (2–3) (1–3) (1–3)
PMD (h) 9–48 h 12–42 9–48 h 11–96
Fixation (months) 2–19 1–19 2–68 1–5
*WM Score; white matter pathology score assessed using scale from [23].
Length of fixation ranged 1–19 months for CADASIL, young controls and SVD samples; and 2–68 months for old controls.
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; GI, gastrointestinal; N/A, not avail-
able; PMD, post mortem interval; SVD, small vessel disease; WM, white matter.
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productno.84541;ThermoScientific); donkeyanti-goat con-
jugated Alexa Fluor 350 (1:500, product no. 1084434; Life
Technologies, Grand Island, NewYork, USA); and goat anti-
mouse conjugated Alexa Fluor 650 (1:500, product
no.84545; Life Technologies). Sections were then washed in
PBS before mounting in Vectashield with DAPI (Vector Labo-
ratories, Burlingame, CA, USA). Images were captured using
LeicaTCS SP2 (upright) and Zeiss Spinning Disk (Invert) con-
focal microscopes (Leica Microsystems, Wetzlar, Germany
and Zeiss Microscopy, Oberkochen, Germany). In situ
co-localizationof twoantibodieswasassessedusing the JaCoP
Plugin for Image J [45]. The Manders co-localization coeffi-
cient used to compare the extent of co-localization between
antibodies.Theoverlapof greenandred (co-localization)anti-
gens was set to be yellow.
Sclerotic index (SI)
Ten-μm sections were stained with H&E haematoxylin and
eosin’ for assessment of the SI of microvessels in the WM.
Briefly, all arterioles with external diameter between 35 and
350 μm within the region of interest were imaged using a
Zeiss Axioplan 2 microscope and Image capture software
(Infinity Capture V4.6.0, Lumenera Corporation). SI was
measured as described previously [25,26], and SI values of
greater than0.3 are considered to be a state of mild SVD, and
those greater than 0.5 are considered to be severe [29].
Statistics
Data were analysed using SPSS (V19.0, IBM Corporation,
Armonk, NY, USA); data were tested for normality using
Shapiro–Wilk test. Differences between means of groups
were first tested using anova and where appropriate
using Tukey’s post hoc test . Linear correlations between
PDGFR-β immunoreactivity and other vascular markers
were performed using the Pearson’s correlation, as
described previously [26]. The points represent %A for 23
pairs of values. Significant difference between means was
considered when the P value was less than 0.05.
Results
Immunohistochemical staining of PDGFR-β
within capillaries
PDGFR-β antibody immunostained pericyte-like cells associ-
ated with capillaries of the smallest internal diameters
(∼6 μm) and some pre-capillaries in both grey matter (GM)
and WM (Figure 1). We also noted some PDGFR-β
immunostaining of pyramidal neurons within the cortex.
Pericytes were identified by their morphology and in cross-
sections evident as typical ‘crescent’ shaped cell bodies,
wrapped closely around capillary walls (Figure 1B). They
werealso observedaround the transverse lengthof capillaries
(Figure 1A,C). Dual IF labelling with GLUT-1 antibodies
revealed the close association between PDGFR-β and
endothelial cells, but thesemarkers labelled different cell types
(Figure 1C,D).
To further differentiate and validate PDGFR-β
immunoreactivity, we performed triple labelling of capil-
laries with PDGFR-β, SMA and GLUT-1 (Figure 2). This
confirmed PDGFR-β immunoreactivity was largely associ-
ated with pericytes in capillaries in the general absence of
SMA reactivity. However, we did observe both PDGFR-β
and SMA immunoreactivities in some larger capillaries
with diameters greater than 10 μm (Figure 2D). In
CADASIL cases, there were often severely degenerating
capillaries, where expression of the endothelial protein
GLUT-1was perturbed and some perivascular cells stained
positive (possibly leaked erythrocytes) for GLUT-1 with
evidence of endothelial blebbing (Figure 2A,B). This was
not frequent in SVD and less so in control.
To assess the relationship between pericytes and N3ECD
deposits or GOM in CADASIL, we first replicated our previous
findings to show thatN3ECD immunoreactivitywas localized
as granular material along capillaries (Figure 3). We then
used dual IF labelling to assess co-localization of PDGFR-β
positive pericytes and N3ECD deposits. We observed N3ECD-
stained granular deposits along capillary walls, indicating an
abundanceof N3ECDand likelyGOMdepositswithin thecap-
illary beds, but these did not always overlap with PDGFR-β-
immunostained cells (Figure 3D). However, upon overall
screening, PDGFR-β positive pericytes were co-localized with
N3ECD in∼70%of theCADASILcases.Usingdual IF labelling
to assess co-localisation between PDGFR-β positive pericytes
andN3ECDdepositswe found strong association between the
two antibodies with the following statistics: Pearson’s r2 =
0.905;Manders’ coefficientsM = 0.969 for fractionof N3ECD
overlapping PDGFR-β, andM = 0.920 for fraction of PDGFR-
β overlappingN3ECD (P < 0.001).This indicated a close rela-
tionship between pericytes with N3ECD deposits or GOM.
Immunohistochemical staining of PDGFR-β
within larger cerebral microvessels
PDGFR-β antibody staining was also observed in
endothelial cell layers, in cells located within the tunica
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media and more diffusely in the adventitia of small arteri-
oles (internal diameter approximately 30 μm) in
CADASIL, SVD cases and less so in controls (Figure 4).
However, diffuse and granular PDGFR-β staining within
the intima was observed in CADASIL subjects where
vessels had undergone hyalinosis (SI >0.5), but to a lesser
extent in SVD (Figure 4). PDGFR-β immunostained
smaller arterioles more frequently, concomitant with
degenerated smooth muscle cells and N3ECD deposits
(Figure 4B,C). Using multiple IF staining for PDGFR-β,
SMA and GLUT-1, we assessed the distribution of the
markers in CADASIL, SVD and controls. We observed that
in both CADASIL and SVD arterioles, there was up-
regulation or enhanced PDGFR-β immunoreactivity in
endothelial cells compared with controls with positive
GLUT-1 but little PDGFR-β immunostaining (Figure
4G–I). In some large arterioles in CADASIL cases, there
was near lack of GLUT-1 reactivity, but strong PDGFR-β
reactivity (Figure 5). We also observed PDGFR-β staining
within the tunica media and adventitia of arterioles more
frequently in CADASIL compared with SVD, and found
concomitant immunostaining for N3ECD alongside
Figure 1. PDGFR-β immunoreactivity in pericyte-like cells around capillaries in the frontal white matter from a CADASIL subject.
(A) Strong PDGFR-β immunostaining in pericytes associated with capillaries within the cortex, with little light staining in neurons. (B)
PDGFR-β only stained capillaries in the white matter. (C) Immunofluorescent labelling with PDGFR-β (green) and GLUT-1 (red) antibodies.
There was differential of the two markers without significant overlap along capillaries, indicating cell-specific GLUT-1 staining in endothelial
cells, and PDGFR-β in perivascular cells. (D) Higher magnification of outlined box in (C), demonstrating PDGFR-β (green) immunostained
pericytes, which appear as classic ‘crescent’ cell bodies with elongated processes stretching around the capillary wall. Haematoxylin
counterstain in A and B. Magnification bar = 20 μm in A, B and D, and 50 μm in C. CADASIL, cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy; PDGFR-β, platelet-derived growth factor receptor-β.
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Figure 2. PDGFR-β immunoreactivity in cerebral microvessels in CADASIL and cerebral SVD. Immunofluorescent labelling of PDGFR-β
(green), smooth muscle α-actin (SMA; magenta) and GLUT-1 (red) in capillaries in the frontal white matter, counterstained with DAPI.
(A and B) Sections from a 68-year-old female CADASIL case with R133C mutation; (B and C), an 81-year-old female patient with sporadic
SVD; (E and F), a 94-year-old nondemented female control. Severe capillary degeneration was observed in CADASIL (A and B), with GLUT-1
expression observed in endothelial cells with blebs, compared with SVD (C and D) and control subject (E and F). There was minimal SMA
immunoreactvity in pericytes (D, arrow) or capillaries. Magnification bar = 33.4 μm in A, 10.4 μm in B, C and D, 15 μm in E and 11.5 μm
in F. CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; PDGFR-β, platelet-derived
growth factor receptor-β; SVD, small vessel disease.
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Figure 3. PDGFR-β immunoreactivity in relation to N3ECD deposits, as a marker of GOM along capillaries in CADASIL. A and B, N3ECD
immunostaining in micro-deposits (GOM) around capillaries. Post mortem human brain tissue from a 68-year-old female CADASIL case with
R133C mutation. (C) PDGFR-β (green) immunostained pericyte in cross-section. (D) N3ECD (red) accumulation around the same pericyte
(as in C). (E) Composite of both PDGFR-β (green) and NOTCH3ECD (red), demonstrating co-localization for both antibodies around the
pericyte. (F) Section of capillary with PDGFR-β (green) and NOTCH3ECD (red) immunoreactivities, demonstrating abundance of N3ECD
deposits (red) associated with the capillary wall. There is some overlap with pericytes within the tissue. Magnification bar = 20 μm in A and
B, 11 μm in C–E, and 24 μm in F. CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
GOM, granular osmiophilic material; PDGFR-β, platelet-derived growth factor receptor-β.
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Figure 4. PDGFR-β immunoreactivity associated with arterioles and cerebral microvessels in CADASIL. (A–C) Immunohistochemical staining
for PDGFR-β (A), SMA (B) and N3ECD (C) in a partially hyalinized arteriole in the white matter of a 44-year-old female CADASIL subject with
R153C mutation. (A) PDGFR-β reactivity was observed in the endothelial cells of arterioles and expressed abluminally to VSMC (arrow) and in
the adventitia. (B) SMA and N3ECD reactivities were predominantly within the tunica media of the same vessel (C). (D–F) PDGFR-β
immunostaining in 49-year-old cognitively normal control female, indicating diffuse PDGFR-β staining within arteriolar walls (D). SMA staining
revealed intact vascular smooth muscle cells (E) without presence of N3ECD aggregates (F). (G–I) Immunofluorescent labelling of PDGFR-β
(green), SMA (magenta) and GLUT-1 (red) in arterioles of the frontal white matter, with DAPI counterstain. (G) Vascular smooth muscle cell
(demonstrated by SMA, magenta) degeneration in arterioles in a 68-year-old female CADASIL case with R133C mutation, with increased
PDGFR-β (green) expression within the vessel wall. (H) Some PDGFR-β (green) reactivity in the endothelial cell layer of arteriole from an
81-year-old female patient with sporadic SVD with mild VSMC degeneration compared with CADASIL (cf. D). (I) PDGFR-β (green) expression was
absent in an arteriole in a 94-year-old nondemented female control, although GLUT-1 (red) and SMA (magenta) appeared normal. (J–L)
Immunofluorescent labelling of PDGFR-β (green), SMA (magenta) and N3ECD (red) in arterioles of white matter, confirming that N3ECD only
accumulated in the tunica media in CADASIL (J), although PDGFR-β (green) immunoreactivity was apparent in both arterioles from CADASIL
(J) and SVD cases (K). (L) GLUT-1 immunostaining in endothelial cells of arteriole of a control subject, whereas PDGFR-β reactivity was meagre,
if any. Scale bar = 50 μm in A–F, 40 μm in G, 27.5 μm in H, 47.5 μm in I, 52 μm in J, 57 μm in K and 49.5 μm in L. CADASIL, cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; PDGFR-β, platelet-derived growth factor receptor-β; SMA,
smooth muscle alpha actin; SVD, small vessel disease; VSMC, vascular smooth muscle cell.
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degeneration of VSMC in CADASIL arterioles, a change
which was not observed in SVD or controls (Figure 4J–L).
Quantitative analysis of PDGFR-β and the
relationship with vascular markers
Quantitative analysis in capillaries in the frontal WM
immunostained for PDGFR-β revealed a trend for differ-
ences in the %A immunoreactivity between groups
(anova, P = 0.084). However, post hoc tests revealed sig-
nificant differences between CADASIL and young control,
and between old and young controls (Tukey’s test,
P < 0.05; Figure 6A).
To assess if PDGFR-β immunostaining was related to
changes in vascular cell markers, we correlated the
PDGFR-β %A determined in the frontal WM against the
endothelial cell marker, GLUT-1 and the basement mem-
branemarker, COL4.We found no association between the
%A immunostaining of PDGFR-β and GLUT-1 (Pearson’s
r = 0.312, P = 0.148, n = 23, Figure 6B). However,
we observed a significant correlation between %A
immunostaining of PDGFR-β and COL4 (Pearson’s
r = 0.529, P = 0.009, n = 23, Figure 6C). We further cal-
culated the PDGFR-β %A: COL4 %A ratio of the CADASIL
cases and observed that there were no significant
differences between the young control and CADASIL
groups, indicating lack of changes in overall PDGFR-β
immunoreacvity per unit amount of COL4 or basement
membrane protein (P > 0.05). To also relate whether arte-
riolar sclerosis in general had any impact on capillary
density, we correlated PDGFR-β immunoreactivity as %A
with SI and found no relationship between %A staining of
PDGFR-β and SI (data not shown).
Discussion
Using immunohistochemical methods, we localized
PDGFR-β immunoreactivity in brains of subjects with
CADASIL and SVD. Concentrating on the WM, we con-
firmed that PDGFR-β positive cells are pericyte-like cells
frequently found around capillaries. These cells are also
associated with N3ECD immunoreactivity, which is a reli-
able marker of GOM in CADASIL [4]. From these static
studies, it is not clear whether pericytes produce or uptake
N3ECD or GOM as a measure for perivascular clearance
[30]. However, our findings are consistent with the postu-
lation that pericytes, identified by electronmicroscopy, are
associated with GOM [5–7] and by extension N3ECD
deposits.
We also showed that there is an increase in PDGFR-β
immunoreactivity associated with pericytes in CADASIL
compared with similar age controls, with a similar trend
in SVD compared with respective older controls. These
results suggest changes in the capillary population of
PDGFR-β-expressing pericytes in the WM in CADASIL.
The findings further suggest that pericyte coverage of
capillaries is robust in CADASIL despite the presence of a
significant burden of N3ECD deposits or GOM in their
proximity. This possibly indicates that the integrity of the
BBB is not completely diminished because it has been
previously shown that the loss of pericytes in PDGF-null
mice impairs the barrier [9]. We also observed that
PDGFR-β immunoreactivity was associated with COL4
immunoreactivity, but not GLUT1 in capillaries. This
suggests that immunoreactivity to PDGFR-β or density of
pericytes was not changed in relation to changes in COL4
reactivity, but does confirm the known relationship
between pericytes and capillary basement membranes
[9]. The lack of a significant relationship between
Figure 5. Immunofluorescent labelling of PDGFR-β (green), SMA
(magenta) and GLUT-1 (red) in an arteriole within the frontal
white matter of a 68-year-old female CADASIL subject with R133C
mutation. Expression of GLUT-1 (red) by endothelial cells was
markedly diminished in this arteriole. However, there was marked
PDGFR-β (green) reactivity. Scale bar is 47.62 μm. CADASIL,
cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; PDGFR-β, platelet-derived growth factor
receptor-β; SMA, smooth muscle alpha actin.
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PDGFR-β and GLUT-1 may partly reflect abnormalities in
endothelial cells, which are also in close proximity to
pericytes [9].
PDGFR-β is known to be up-regulated in response to
hypoxia [19,31] and its expression can be induced in dif-
ferent cell types under different conditions [32]. A recent
reported a significant reduction in the number of pericytes
following acute stroke, followed by proliferation of
PDGFR-β+ cells of neurovascular origin during scar for-
mation [31]. However, this study utilized a model of acute
large artery occlusion which produces a large ischaemic
lesion [31], a process not common to CADASIL or SVD
[2,3]. Instead, CADASIL is known to undergo slow insidi-
ous progression withmultiple small strokes (and transient
ischaemic attacks), resulting in microinfarcts and an
overall loss of axonal myelin without relatedWM changes
[2,3,26].We therefore postulate a differential involvement
of PDGFR-β-expressing pericytes in CADASIL and possibly
SVD, where a chronic hypoxic state [33] or low levels of
transient hypoxiamay up-regulate various factors such as
bone morphogenic protein-4 (Maiko Uemura and
Masafumi Ihara, pers. comm.), which co-localizes with
PDGFR-β and may in turn affect its expression in
pericytes. This, however, does not result in large-scale
increases in PDGFR-β-cells migrating into the paren-
chyma to form scar tissue.
PDGF is also expressed by endothelial cells during
angiogenesis to attract PDGFR-β-expressing pericytes to
capillary walls, where PDGF acts as a downstream of
angiogengic signal, which in turn increases in response to
hypoxic signals [15,34]. Further to involvement in
pericyte recruitment in angiogenesis, PDGF expression
interacts with Notch signalling, where both Notch1 and
Notch3 ligands promoted PDGFR-β expression in cultured
VSMC through independent mechanisms, but both recep-
Figure 6. Quantification of PDGFR-β immunoreactivity in the
frontal white matter in CADASIL. (A) Quantitative analysis of
PDGFR-β percent area (%A) revealed a trend for differences
between the groups (anova, P = 0.084, n = 6–7 samples per
group). However, post hoc tests revealed significant differences
between CADASIL subjects and young controls, and the old control
group compared with young controls (Tukey’s test, *P < 0.05). (B)
Lack of relationship between PDGFR-β %A and GLUT-1
immunoreactivity (r = 0.312, P = 0.148). (C) PDGFR-β %A was
significantly correlated with the basement membrane marker COL4
(r = 0.529, P = 0.009). CADASIL, cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy;
PDGFR-β, platelet-derived growth factor receptor-β.
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tors appear to instigate increased functional PDGFR-β
expression [21]. This mechanismmay serve to transiently
attenuate VSMC phenotype in response to extracellular
cues. A muted response of PDGFR-β up-regulation in cul-
tured VSMC from a CADASIL patient with the R133C
NOTCH3 mutation [21], a version of NOTCH3 receptor
thought to be hypomorphic, although the functional phe-
notype of CADASIL associated NOTCH3mutations, is still
under debate [35,36]. These findings may explain the
observed increase in PDGFR-β staining in capillaries of
CADASIL, where dysfunctional NOTCH3 mutant proteins
present in CADASIL result in an exacerbated response of
PDGF and PDGFR-β expression in states of hypoxia to
promote angiogenesis.
We observed PDGFR-β reactivity in endothelial cells of
small arterioles, where the staining was more intense fre-
quently in CADASIL. We further observed (qualitative)
diffuse PDGFR-β immunostaining within the vessel wall,
specifically in the small arterioles, which had undergone
sclerosis of the vessel wall. PDGF signalling has been asso-
ciatedwith other vascular pathologies, such as atheroscle-
rosis [37,38], kidney fibrosis [39], lung fibrosis [32],
pulmonaryarterial hypertension (PAH) [40,41]anddiabe-
tes [42]. Some of these vascular disorders exhibit similar
pathophysiology to thoseobserved inarteriolosclerosis and
hyalinosis of arterioles commonly observed in dementing
cerebrovasculardisorders,wherevessels exhibit significant
vessel wall thickening, increased collagen deposition and
changes in VSMC morphology [26]. Similarly, in athero-
sclerosis and arterial restenosis, VSMCs de-differentiate
from their contractile state towards a less specialized cell
type, switching to a synthetic phenotype and migrating
into the intimawhere theyundergoproliferation, amecha-
nismregulated byPDGFR-β signalling [32,37,42].Wepre-
viously reported that SVD and CADASIL cases exhibit
increased arteriolosclerosis in the frontal WM [26]. Taken
together, our results suggest that increased PDGFR-β in
endothelial cells of arteriolesmaybe linked todegeneration
of VSMC and vessel wall hyalinosis.
Our results suggest that there is a similar mechanism
responsible for the vessel sclerosis observed in small vessel
diseases of the brain as that which has been reported in
other systemic disorders, where an increase in PDGF sig-
nalling is initiated by a primary vascular disorder such as
hypertension or diabetes. This PDGF signal results in a
phenotype conversion of VSMCs from contractile to a syn-
thetic phenotype, which would function to reduce the
contractile ability of the blood vessel and therefore a loss of
autoregulation of cerebral blood flow. Once the VSMCs
begin to dedifferentiate, the control of local blood flow
may be attenuated, resulting in further states of hypoxia,
which in turn up-regulates the Notch and PDGF path-
ways, and the vessel is further impeded in a vicious cycle.
Although the consequences of CADASIL-causing muta-
tions are debated [35,36], NOTCH3 mutations might be
considered the primary factor in the disease process, and
the similarities between CADASIL and SVD could be
explained by NOTCH3 polymorphisms associated with
late-onset SVD [35,43], where presence of a hypomorphic
NOTCH3 phenotype may render a patient more vulner-
able to ischaemic processes occurring as a result of other
environmental damage to blood vessel walls, such as
hypertension.
Our study is not without limitations. The availability of
a larger pool of brain samples would have permitted more
in-depth characterization of the PDGFR-β-expressing
pericytes in the WM regions. The availability of more spe-
cific markers of pericytes would also have been useful to
verify our findings. However, our initial study is suffi-
ciently novel to suggest that the persistent hypoxic state
within the deep WM [44] may reflect activation of
capillary-associated pericytes in CADASIL. The signifi-
cance of these findings is important for both CADASIL and
SVD subjects, where agents, whichmodulate PDGF signal-
ling,may provide therapeutic strategies to reduce themor-
bidity in cerebral SVDs.
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